Diabetic Neuropathy Market Innovations: Advancing Treatment Options

 Diabetic neuropathy is a medical condition that arises due to nerve damage in the body of people suffering from diabetes. It negatively impacts the proper functioning of various body parts like feet or legs. Left untreated, it can even lead to amputation. The various products available in the market for managing diabetic neuropathy include medicines and therapeutic devices. Medicines like pregabalin and duloxetine are effective in treating the symptoms of pain, nerve damage and numbness associated with diabetic neuropathy. Therapeutic devices help stimulate nerves and improve blood circulation. The global Diabetic Neuropathy Market is estimated to be valued at US$ 3626.38 mn in 2023 and is expected to exhibit a CAGR of 6.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The rising cases of diabetes across the world, mainly due to obesity, sedentary lifestyles and unhealthy eating habits, has fueled the occurrences of diabetic neuropathy as its complication. It is estimated that over 460 million people globally were suffering from diabetes in 2019, and this number is expected to surge to 700 million by 2045. As a result of steep rise in diabetes prevalence, the instances of diabetic neuropathy have also grown substantially. As per some estimates, approximately 50% of all diabetic patients eventually suffer from some level of neuropathy condition. Therefore, the exploding diabetes population worldwide has emerged as a key growth driver for the diabetic neuropathy drugs market. The growing diabetes burden and its neurological complication have compelled individuals to seek effective treatment options, thus boosting the demand for neuropathy therapeutics over the forecast period.

Segment Analysis
The global diabetic neuropathy market can be segmented based on indication, treatment type, and end user. Among indication, diabetic peripheral neuropathy accounts for the largest market share owing to rising prevalence of diabetes and its complications. Among treatment, drugs is the dominating segment as drugs are the first line treatment options for diabetic neuropathy. Drugs cover majority of market share as they provide safe and effective pain relief.

Key Takeaways
The global diabetic neuropathy market is expected to witness high growth over the forecast period. The market is set to grow at a CAGR of over 6.9% during 2023 to 2030 to reach a value of over USD 3626.38 million by 2024.

Regional analysis: North America dominates the global diabetic neuropathy market and is expected to continue its dominance over the forecast period. This is attributed to growing prevalence of diabetes, availability of advanced treatment options and early diagnosis rate in the region. Asia Pacific is anticipated to witness fastest growth owing to growing patient population, improving healthcare infrastructure and flourishing medical tourism in the region.

Key players operating in the diabetic neuropathy market are Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals. Eli Lilly is one of the prominent players offering drugs such as pregabalin and duloxetine for diabetic neuropathy pain management. GlaxoSmithKline is also a leading player providing strong drugs portfolio in the market.

Diabetic Neuropathy Market Analysis: Understanding Patient Needs

 

Diabetic neuropathy, also known as diabetic nerve damage, refers to damage to nerves due to diabetes. It is caused by high blood sugar levels damaging nerves over time. Symptoms range from pain or numbness to an increased susceptibility to injury. There is also currently no cure for diabetic neuropathy. The global Diabetic Neuropathy Market is estimated to be valued at US$ 3626.38 mn in 2024 and is expected to exhibit a CAGR of 6.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Increasing prevalence of diabetes around the world is expected to be a key driver for growth of the diabetic neuropathy market over the forecast period. According to estimates by the World Health Organization, the global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014. This is expected to increase further in the coming years. Diabetes induced nerve damage affects between 30-50% of all people with diabetes. As a result, the rising diabetes patient pool globally will correspondingly raise demand for treatments and therapeutics for diabetic neuropathy management over the forecast period.

Segment Analysis
The global diabetic neuropathy market is segmented based on indication, treatment type, and end user. By indication, the diabetic peripheral neuropathy segment currently dominates the market due to rising number of diabetic patients suffering from nerve damage. By treatment type, the drugs segment holds the highest market share as drugs such as pregabalin, duloxetine, and gabapentin are widely prescribed for pain management.

Key Takeaways
The global diabetic neuropathy market is expected to witness high growth over the forecast period due to the rising global burden of diabetes.

Regional analysis: North America currently leads the global market and is expected to maintain its dominance during the forecast period. This is attributed to growing diabetic population, rising healthcare expenditure, and presence of key players in the region. Asia Pacific is anticipated to witness the highest growth rate owing to increasing incidence of diabetes, growing medical tourism, and improving healthcare infrastructure in emerging countries.

Key players: Key players operating in the diabetic neuropathy market are Eli Lilly and Company, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals. Eli Lilly and Company offers pregabalin under the brand name Lyrica for neuropathic pain associated with diabetic peripheral neuropathy. Pfizer provides duloxetine under the brand name Cymbalta for managing diabetic neuropathic pain and depressive disorders.

Diabetic Neuropathy Market Echo: Amplifying Impact in Diabetes-Related Nerve Damage

 Diabetic neuropathy is a common complication of diabetes that damages the peripheral nerves resulting in numbness and pain in hands and feet. Conditions such as peripheral diabetic neuropathy impairs sensation, motor function and autonomic nervous system functions impacting a patient's quality of life. Therapies that can relieve symptoms include anticonvulsants, antidepressants and opioids. The global Diabetic Neuropathy Market is estimated to be valued at US$ 3,626.38 Mn in 2023 and is expected to exhibit a CAGR of 6.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Increased adoption of novel therapies is one of the key trends driving the growth of the diabetic neuropathy market. Drug manufacturers are introducing new treatment options to effectively manage neuropathic pain associated with diabetic neuropathy. For instance, Eli Lilly and Company’s investigational treatment tanezumab which is a non-opioid treatment for chronic pain due to diabetic neuropathy. If approved, tanezumab will provide an alternative to current treatment standards including opioids. Similarly, Johnson & Johnson is evaluating efficacy and safety of amitriptyline for moderate to severe painful diabetic neuropathy. Amitriptyline is an antidepressant that effectively relieves nerve pain. These novel treatment options that demonstrate superior efficacy and safety profile will enable higher treatment rates fueling the diabetic neuropathy market growth over the forecast period.

Segment Analysis
The global Diabetic Neuropathy market is segmented on the basis of type, drugs, and end users. The type segment is further divided into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. Peripheral neuropathy dominates other sub segments due to high prevalence of peripheral nerve damage in diabetic patients. This segment accounts for over 60% of market share as most cases of diabetic neuropathy are associated with damage to peripheral nerves.

Key Takeaways

The global Diabetic Neuropathy market is expected to witness high growth during the forecast period from 2023 to 2030. The market is projected to grow at a CAGR of 6.9% during this period and reach a market size of USD 3626.38 Mn by 2023.

Regional analysis

North America is currently the largest and fastest growing regional market for diabetic neuropathy. High prevalence of diabetes and growing awareness about treatment and management of diabetic neuropathy are major factors driving market growth in this region. The US dominates the North American as well as global market and accounts for over 50% revenue share.

Key players

Key players operating in the Diabetic Neuropathy market are Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals. Eli Lilly and Company dominates the global market with its product duloxetine being one of the leading therapy options for diabetic neuropathy treatment worldwide.